查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2001035

鞘內泵市場：2026-2032年全球市場預測（按泵類型、藥物類型、治療領域和最終用戶分類）

Intrathecal Pumps Market by Pump Type, Drug Type, Therapy Area, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，鞘內幫浦市場價值將達到 17.3 億美元，到 2026 年將成長至 18.6 億美元，到 2032 年將達到 31.5 億美元，複合年成長率為 8.88%。

主要市場統計數據
基準年 2025 17.3億美元
預計年份：2026年 18.6億美元
預測年份 2032 31.5億美元
複合年成長率 (%) 8.88%

權威說明概述了鞘內泵療法的發展歷程、臨床重點、監管期望以及影響其實施的相關人員決策因素。

鞘內泵療法已從一種小眾臨床干預手段發展成為全身性治療無效或副作用難以接受時，治療複雜疼痛和痙攣的核心工具。在過去十年間，臨床醫生拓展了其適應症並最佳化了患者選擇標準，而工程師則提高了設備的可靠性、藥物傳輸的精確度和可編程性。因此，鞘內泵生態系統如今已成為眾多相關人員的交匯點，包括植入醫生、設備製造商、醫院採購團隊、門診中心、保險公司以及尋求持續症狀控制並降低全身風險的患者。

設備工程、遠端監測、臨床實踐和監管預期等方面的創新融合，將如何重塑部署路徑和護理服務模式？

由於技術、臨床實踐和醫療服務模式等多面向因素的融合，鞘內幫浦領域正經歷著變革性的轉變。設備層面的創新優先考慮耐用性和精準性，電池和導管介面的逐步改進正在降低再次手術率並提高患者的便利性。同時，遠端監測和數位遙測技術的整合能夠更早發現設備相關併發症並更快地調整劑量，最終影響後續工作流程和臨床資源的分配。

詳細分析了 2025 年價格調整如何迫使供應鏈快速調整、籌資策略和設計變更，以保護臨床連續性和獲利能力。

2025年的貿易政策變化和關稅調整為鞘內泵的供應鏈和籌資策略帶來了新的不穩定性。某些醫療設備組件和進口子組件關稅的提高，推高了依賴地理分散生產網路的製造商的投入成本。為因應這一變化，各組織加快了供應商多元化策略，重新評估了採購地點，並優先選擇在前置作業時間和價格方面提供更高透明度和柔軟性的供應商合約。除了這些供應方面的應對措施外，各組織還採取了營運方面的調整，例如增加關鍵導管和電子元件的庫存緩衝，以及更嚴格的組件認證流程。

全面的細分洞察揭示了醫療設備類型、藥物選擇、治療適應症和醫療保健環境如何相互交織，從而決定臨床工作流程和商業化策略。

了解治療效果和商業化路徑需要對鞘內泵的市場結構進行深入觀點，包括產品和臨床細分。根據幫浦的類型，治療方案可分為兩類：用於短期或住院治療的體外輸注系統和用於長期慢性鞘內治療的植入式幫浦。每種幫浦都有其獨特的易用性、感染控制和維護的考量。這些器械類別決定了臨床醫生的工作流程，並影響治療的開展地點。植入式系統通常需要在手術環境下進行，並需要長期隨訪，而體外裝置則通常適用於急性期或過渡期治療。

關鍵區域見解解釋了美洲、歐洲、中東和非洲以及亞太地區在監管、償還和基礎設施現實方面的差異如何影響部署和准入策略。

區域趨勢正在影響整個鞘內幫浦領域的臨床應用、監管互動和供應鏈設計。在美洲，緊密的學術機構和地方醫院網路，以及強力的核准後臨床研究，促進了早期應用。這些地區複雜的報銷機制和支付方的嚴格審查影響著申辦者對證據產生的優先排序。同時，一體化的醫院系統能夠建構支援長期追蹤和設備維護的整合式診療路徑。因此，製造商越來越傾向於根據醫療系統的證據需求和價值驗證試點計畫來調整其打入市場策略。

從公司層面深入分析，揭示了成熟製造商和創新新參與企業如何透過臨床證據、服務模式和軟體驅動的差異化競爭。

鞘內幫浦市場的競爭動態反映了現有設備的可靠性與新興的、針對特定臨床需求的專業創新者之間的平衡。成熟的製造商憑藉長期的臨床數據、廣泛的服務網路和綜合培訓項目保持優勢，這些優勢能夠降低植入風險並支持後續護理。這些優勢有助於建立機構信任，並簡化醫院和專科診所的採購決策，因為這些機構的臨床團隊需要高可靠性和完善的售後支援。

為醫療設備製造商、臨床醫生和支付方提供實用建議，以協調證據、數位化能力、供應鏈彈性和經營模式，以實現永續成長。

產業領導者需要採取果斷行動，使產品藍圖、臨床證據產生和供應鏈韌性與不斷發展的醫療服務模式保持一致。應優先進行整合價值論證，將醫療設備性能與具有臨床意義的結局聯繫起來，例如減少全身用藥、降低住院率以及改善痙攣患者的功能狀態。儘早與支付方和大規模醫療系統合作，並制定切實可行的證據收集舉措，可以縮短報銷審核週期，並支持基於價值的合約試點專案。

為了確保獲得可操作的見解，我們採用透明、嚴謹的調查方法，結合了對臨床醫生的訪談、監管和文獻審查、供應鏈分析以及專家檢驗。

本研究整合了多種調查方法，以確保研究結果的嚴謹性和可重複性。在初步調查中，我們對實施植入手術的醫生、採購經理和臨床專案經理進行了結構化訪談，以了解實際操作情況、患者選擇標準和後續工作流程。除了這些第一線人員的觀點外，臨床顧問小組的討論檢驗了臨床假設，並確定了在不同醫療環境中推廣鞘內治療的實際障礙。

簡潔的結論強調了在創造臨床價值、確保供應彈性以及使證據與支付方和提供者的需求保持一致方面所面臨的策略挑戰。

鞘內幫浦治療正處於轉折點，臨床潛力、技術能力和政策趨勢在此交匯，為相關人員創造了新的機會和責任。設備設計和遙測技術的進步正在推動更安全、以患者為中心的護理模式的發展，而不斷提高的支付方期望和監管審查則要求提供更強力的證據和更完善的生命週期管理。 2025年的定價經驗凸顯了分散式供應鏈的脆弱性，以及製定策略性彈性規劃以確保治療連續性的必要性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 鞘內幫浦市場：依幫浦類型分類

  • 外置泵
  • 嵌入式泵浦

第9章：按藥物類型分類的鞘內泵市場

  • Baclofen
  • 局部麻醉劑
  • 鴉片類藥物

第10章：依治療領域分類的鞘內幫浦市場

  • 疼痛管理
    • 癌症疼痛
    • 慢性非癌性疼痛
  • 痙攣管理
    • 腦性麻痹
    • 多發性硬化症
    • 脊髓損傷

第11章 鞘內幫浦市場：依最終用戶分類

  • 門診手術中心
  • 醫院
  • 專科診所

第12章 鞘內幫浦市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 鞘內幫浦市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 鞘內幫浦市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國鞘內幫浦市場

第16章：中國鞘內幫浦市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Arrow International, Inc.
  • Arthrex, Inc.
  • B. Braun Melsungen AG
  • Baxter International Inc.
  • Becton Dickinson and Company
  • Boston Scientific Corporation
  • Durect Corporation
  • Flowonix Medical, Inc.
  • Fresenius Kabi AG
  • Johnson & Johnson Services Inc.
  • Medallion Therapeutics, Inc.
  • Medtronic plc
  • Smiths Medical
  • Teleflex Inc.
  • Terumo Corporation
  • Tricumed Medizintechnik GmbH
  • Zimmer Biomet Holdings, Inc.
Product Code: MRR-205091A8875F

The Intrathecal Pumps Market was valued at USD 1.73 billion in 2025 and is projected to grow to USD 1.86 billion in 2026, with a CAGR of 8.88%, reaching USD 3.15 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.73 billion
Estimated Year [2026] USD 1.86 billion
Forecast Year [2032] USD 3.15 billion
CAGR (%) 8.88%

An authoritative introduction that frames intrathecal pump therapy evolution, clinical priorities, regulatory expectations, and stakeholder decision drivers shaping adoption

Intrathecal pump therapy has matured from a niche clinical intervention to a central tool for managing complex pain and spasticity when systemic therapies fail or cause unacceptable side effects. Over the past decade clinicians have expanded indications and refined patient selection, while technologists have improved device reliability, drug delivery precision, and programmability. As a result, the intrathecal pump ecosystem now intersects diverse stakeholders: implanting physicians, device manufacturers, hospital procurement teams, ambulatory centers, payers, and patients seeking durable symptom control with fewer systemic risks.

The introduction of advanced infusion algorithms and integrated telemetric monitoring has shifted discussions from simply whether to use intrathecal delivery toward how to optimize long-term therapy in outpatient settings. Concurrently, regulatory agencies have sharpened focus on post-market surveillance and device-human interface risks, prompting manufacturers to invest in clinical evidence and lifecycle management. Taken together, these developments demand that clinical leaders and commercial strategists navigate a more complex environment where safety, outcomes, service, and cost-efficiency determine adoption trajectories rather than device novelty alone.

This executive summary synthesizes the clinical, commercial, and policy dynamics shaping intrathecal pump therapy today. It frames the transformational shifts influencing stakeholder decisions, highlights tariff-driven supply chain implications for 2025, and distills segmentation, regional, and competitive insights actors must consider. The goal is to provide a coherent, actionable foundation for executives and clinical leaders to align product development, market access, and operational strategies with evolving patient and system needs.

How converging innovations in device engineering, remote monitoring, clinical practices, and regulatory expectations are reshaping adoption pathways and care delivery models

The intrathecal pump landscape is undergoing transformative shifts driven by converging forces in technology, clinical practice, and healthcare delivery models. Device-level innovation has prioritized longevity and precision; batteries and catheter interfaces have seen incremental improvements that reduce revision rates and improve patient convenience. Simultaneously, the integration of remote monitoring and digital telemetry is enabling earlier detection of device-related complications and more responsive dose titration, which in turn influences follow-up workflows and clinic resource allocation.

Clinical practice is shifting from episodic in-clinic programming to hybrid monitoring models that combine periodic in-person assessments with data-driven remote adjustments. This evolution supports broader use of ambulatory surgical centers for implantation and follow-up, altering traditional hospital-centered referral patterns. At the same time, heightened attention to opioid stewardship and growing evidence for intrathecal baclofen in spasticity care have expanded conversations around patient selection criteria and long-term management pathways. These clinical shifts are creating new expectations for evidence generation, patient education, and multidisciplinary care coordination.

Regulatory and reimbursement environments are also evolving. Agencies are prioritizing robust post-market surveillance and clearer labeling on device-drug combinations, requiring manufacturers to demonstrate lifecycle safety. Payers are scrutinizing long-term value propositions more closely, looking beyond acute procedural costs to outcomes such as reduction in systemic drug use, hospitalization, and caregiver burden. As a result, commercial strategies increasingly emphasize real-world evidence collection, value-based contracting pilots, and partnerships with health systems to demonstrate integrated care pathways that support both clinical outcomes and economic objectives.

Taken together, these transformative shifts are reshaping not just product roadmaps but also the operational and commercial architectures required to scale intrathecal therapies. Effective stakeholders will be those that harmonize device performance with care delivery innovations and evidence generation to lower barriers to adoption and secure long-term therapeutic partnerships with providers and payers.

A focused analysis of how 2025 tariff shifts forced rapid supply chain adaptation, procurement strategies, and design changes to protect clinical continuity and margins

Trade policy changes and tariff adjustments in 2025 introduced a new variable into intrathecal pump supply chains and procurement strategies. Increased duties on select medical device components and imported subassemblies elevated input costs for manufacturers that rely on geographically distributed production networks. In response, organizations accelerated supplier diversification strategies, re-evaluated sourcing footprints, and prioritized supplier contracts that provide greater transparency and flexibility around lead times and pricing. These supply-side responses have been complemented by operational changes such as increased inventory buffers for critical catheter and electronic components and more rigorous component qualification processes.

Clinicians and hospital procurement teams observed the downstream effects through intermittent lead-time extensions and more frequent allocation prioritization for urgent cases. Ambulatory surgical centers reported heightened attention to stock management as shorter-term suppliers struggled to absorb tariff-related cost pressures. In parallel, some manufacturers implemented targeted price adjustments or revised service contracts to offset increased input costs while protecting access to essential therapies for high-acuity patients.

Policy uncertainty surrounding tariff permanence encouraged several strategic pivots that may endure beyond 2025. Manufacturers intensified nearshoring and localization efforts to reduce exposure to cross-border duties, while contract manufacturers expanded capacities in lower-tariff jurisdictions. Additionally, there was accelerated interest in design-for-supply resilience, where component standardization and modularization reduce dependence on single-source, tariff-exposed parts. These adaptations improved medium-term supply continuity but also required capital investment and cross-functional coordination, affecting short-term margins and product rollout timelines.

For healthcare leaders, the lesson from the 2025 tariff environment is that supply chain resilience is now a strategic dimension of clinical continuity planning. Procurement teams and device sponsors increasingly collaborate on contingency planning, including dual-sourcing strategies and visibility into upstream supplier risk. As tariff volatility persists as a planning consideration, organizations that embed flexible sourcing, buffer strategies, and proactive supplier engagement into their operating models will be better positioned to sustain therapy availability and protect patient care pathways.

Comprehensive segmentation insights revealing how device type, drug selection, therapeutic indication, and care setting intersect to determine clinical workflows and commercialization tactics

Understanding outcomes and commercialization pathways requires a granular view of the product and clinical segmentation that structures the intrathecal pump landscape. Based on pump type, the therapeutic continuum spans externally wearable infusion systems intended for short-term or hospital-based use and implantable pumps designed for chronic long-term intrathecal therapy, each presenting distinct usability, infection control, and maintenance considerations. These device categories inform clinician workflows and influence where care is delivered; implantable systems typically demand surgically oriented settings and long-term follow-up infrastructure, whereas external devices often align to acute or transitional care episodes.

Drug formulation and compatibility directly shape clinical protocols and labeling. Based on drug type, intrathecal therapy incorporates agents such as baclofen for targeted spasticity control, local anesthetics that permit regional analgesia, and opioids deployed for refractory cancer and severe chronic pain. Each drug class brings unique tolerance profiles, dosing paradigms, and monitoring requirements, and clinicians calibrate device programming and follow-up frequency to mitigate risks like catheter-related granulomas or systemic adverse effects. The selection of an intrathecal agent therefore tightly couples pharmacology with device selection and patient counseling.

Therapeutic application further refines care pathways. Based on therapy area, intrathecal interventions serve pain management and spasticity management domains. Pain management itself divides into cancer pain and chronic noncancer pain, with implant choice, opioid stewardship practices, and palliative care integration differing substantially between these populations. Spasticity management encompasses conditions such as cerebral palsy, multiple sclerosis, and spinal cord injury, each with distinct functional goals, multidisciplinary care needs, and long-term rehabilitation implications. Tailoring device features and service models to these clinical subpopulations enhances adherence and functional outcomes.

End-user dynamics are equally influential for deployment and service models. Based on end user, adoption pathways include ambulatory surgical centers, hospitals, and specialty clinics, each carrying different operational capabilities, reimbursement environments, and staffing models. Ambulatory surgical centers are increasingly attractive for elective implant procedures due to efficiency and patient preference, whereas hospitals often manage more medically complex cases and perioperative risks. Specialty clinics that provide longitudinal device programming and multidisciplinary follow-up are essential for maintaining therapy effectiveness and capturing outcomes data. Recognizing how these segmentation lenses intersect is critical for designing go-to-market approaches, clinician education programs, and long-term service offerings that align with real-world care delivery.

Key regional insights explaining how distinct regulatory, reimbursement, and infrastructure realities across the Americas, EMEA, and Asia-Pacific shape adoption and access strategies

Regional dynamics influence clinical adoption, regulatory engagement, and supply chain design across the intrathecal pump landscape. In the Americas, a dense network of academic centers and community hospitals has supported early adoption combined with robust post-approval clinical research. This region's reimbursement complexity and payer scrutiny influence how sponsors prioritize evidence generation, while consolidated hospital systems enable integrated care pathways that support long-term follow-up and device maintenance. Consequently, manufacturers often align market access strategies with health system evidence needs and value demonstration pilots.

Europe, the Middle East, and Africa present heterogeneous regulatory and reimbursement environments that compel flexible market-entry strategies. Western European countries generally emphasize comparative effectiveness and health technology assessment frameworks, prompting manufacturers to invest in real-world outcomes and cost-effectiveness studies. In contrast, parts of the Middle East and Africa may prioritize access and infrastructure development, creating opportunities for targeted capacity-building programs and local partnerships. Cross-border regulatory harmonization efforts and centralized procurement mechanisms in certain jurisdictions can accelerate technology adoption when evidence and service support are aligned.

Asia-Pacific exhibits a mix of mature markets with established regulatory pathways and emerging markets characterized by rapid investment in specialty care infrastructure. In advanced economies within the region, clinical innovators and private healthcare systems drive demand for high-performance devices and integrated service models. In emerging markets, demand is often shaped by investments in surgical capacity, changing disease burdens, and localized reimbursement decisions. Manufacturers seeking regional scale frequently adopt hybrid approaches that combine direct presence in mature markets with distributor partnerships and training programs in developing markets to ensure appropriate clinical adoption and continuity of care.

Across regions, common themes emerge: the necessity of local evidence generation, the importance of training clinical teams for implantation and follow-up, and the value of supply chain resilience. Tailoring commercial and clinical strategies to regional regulatory, payer, and infrastructural realities accelerates adoption while ensuring therapies remain accessible and clinically effective across diverse healthcare systems.

Key company-level insights showing how established manufacturers and innovative entrants compete through clinical evidence, service models, and software-enabled differentiation

Competitive dynamics in the intrathecal pump space reflect a balance between incumbent device reliability and the emergence of specialized innovators targeting niche clinical needs. Established manufacturers maintain advantages through long-term clinical data, extensive service networks, and integrated training programs that reduce implantation risk and support follow-up care. These capabilities foster institutional trust and simplify procurement decisions for hospitals and specialty clinics where clinical teams demand high reliability and robust post-market support.

At the same time, newer entrants and adjacent medical technology firms are differentiating through software-enabled features, remote monitoring, and modular design concepts that emphasize ease of programming and reduced maintenance burden. Such offerings appeal to health systems focused on outpatient care models and to specialists seeking finer titration capabilities. Collaboration between device developers and pharmaceutical sponsors has also intensified, particularly for drug-device combination strategies where co-development can streamline labeling and clinical trial design.

Service and commercial models are increasingly central to competitive positioning. Companies that offer comprehensive clinician training, local technical support, and transparent warranty and replacement policies create stickiness in clinical pathways. Additionally, vendors that invest in outcomes registries and real-world evidence initiatives build stronger value narratives with payers and health systems. Strategic partnerships with hospitals, academic centers, and rehabilitation networks further extend reach and support adoption by embedding devices within established care pathways.

For buyers and health system leaders, vendor selection now hinges on a broader set of criteria than device features alone. Total cost of therapy, service quality, evidence commitments, and the ability to collaborate on pathway redesign have become equally important. Consequently, suppliers that integrate clinical support, data services, and flexible commercial arrangements are better positioned to capture long-term partnerships and scale intrathecal therapy within complex care delivery ecosystems.

Actionable recommendations for device makers, clinicians, and payers to align evidence, digital capabilities, supply resilience, and commercial models for sustainable growth

Industry leaders must act decisively to align product roadmaps, clinical evidence generation, and supply chain resilience with evolving care delivery models. First, prioritize integrated value demonstrations that link device performance to clinically meaningful outcomes such as reduced systemic medication use, lower hospitalization rates, and improved functional status for spasticity patients. Engaging payers and large health systems early to design pragmatic evidence collection initiatives will shorten reimbursement deliberations and support value-based contracting pilots.

Second, invest in remote monitoring and telemetric capabilities that enable hybrid follow-up models and reduce the frequency of in-person visits without compromising safety. Remote data streams not only enhance patient convenience but also provide real-world endpoints that strengthen economic narratives. Complement these technical investments with clinician training programs that prepare broader surgical and specialty clinic networks to adopt implantation and programming protocols, which will expand suitable care settings beyond tertiary centers.

Third, build supply chain strategies that emphasize dual sourcing, localized manufacturing where feasible, and design-for-supply approaches that reduce dependence on tariff-exposed components. Strategic inventory management and supplier partnerships can buffer against short-term disruptions while preserving margins. Simultaneously, cultivate partnerships with rehabilitation and palliative care providers to embed intrathecal therapy within multidisciplinary care pathways, thereby improving patient identification and continuity of care.

Finally, structure commercial models around service and outcomes, not just hardware sales. Offer flexible contracting, warranty packages, and outcomes-based components where feasible to align incentives with purchasers. By integrating evidence generation, digital capabilities, and resilient operations into a coherent go-to-market strategy, industry leaders will be better equipped to scale therapies while addressing payer scrutiny and clinician expectations.

A transparent and rigorous research methodology combining clinician interviews, regulatory and literature review, supply chain analysis, and expert validation to ensure actionable insights

This research synthesizes multiple methodologies to ensure rigorous, reproducible insights. Primary research included structured interviews with implanting physicians, procurement leaders, and clinical program managers to capture operational realities, patient selection criteria, and follow-up workflows. These first-hand perspectives were complemented by clinician advisory panel discussions that validated clinical assumptions and highlighted practical barriers to scaling intrathecal therapies in diverse care settings.

Secondary research encompassed regulatory documentation, peer-reviewed clinical literature, and procedural best-practice guidelines to triangulate safety signals and device performance themes. Product technical specifications and service model descriptions were analyzed to identify emerging design trends and vendor capabilities. Additionally, analysis of clinical registry abstracts and published outcomes studies informed the synthesis of therapeutic and safety narratives specific to baclofen therapy, local anesthetic use, and opioid-based intrathecal interventions.

Supply chain and policy analysis drew on customs and trade publications, publicly available tariff schedules, and procurement case studies to assess the operational impact of 2025 tariff changes. Scenario analysis techniques were applied to evaluate plausible supply-side responses, including nearshoring, dual sourcing, and inventory strategies, and to understand their implications for manufacturers and healthcare providers. Throughout the study, findings were validated through cross-functional expert review to ensure practical relevance and factual accuracy.

The research approach prioritized transparency and reproducibility. Data gaps were documented and addressed through follow-up interviews or conservative interpretation, and limitations are clearly delineated to support appropriate application of insights. This methodological rigor ensures that conclusions are grounded in current clinical practice, regulatory realities, and operational constraints faced by stakeholders in the intrathecal pump ecosystem.

A concise conclusion highlighting the strategic imperatives for capturing clinical value, ensuring supply resilience, and aligning evidence with payer and provider needs

Intrathecal pump therapy stands at an inflection point where clinical promise, technological capability, and policy dynamics converge to create new opportunities and responsibilities for stakeholders. Advances in device design and telemetry are enabling safer, more patient-centric care models, while evolving payer expectations and regulatory attention demand stronger evidence and lifecycle stewardship. The 2025 tariff experience underscored the fragility of distributed supply chains and the strategic necessity of resilience planning to protect therapy continuity.

Segmentation across pump type, drug selection, therapy area, and end-user setting highlights that successful adoption depends on aligning product features with clinical workflows and support services. Regional differences in regulatory expectations and infrastructure further require tailored market approaches. Competitive differentiation is increasingly determined by the quality of service, evidence generation, and digital integration rather than hardware specifications alone.

Looking ahead, stakeholders that integrate robust real-world evidence programs, invest in remote monitoring, and fortify supply chain flexibility will be best positioned to expand access and demonstrate long-term value. Collaboration across manufacturers, clinical networks, and payers will accelerate adoption pathways and ensure that intrathecal therapies deliver meaningful outcomes for patients with complex pain and spasticity needs.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Intrathecal Pumps Market, by Pump Type

  • 8.1. External Pumps
  • 8.2. Implantable Pumps

9. Intrathecal Pumps Market, by Drug Type

  • 9.1. Baclofen
  • 9.2. Local Anesthetics
  • 9.3. Opioids

10. Intrathecal Pumps Market, by Therapy Area

  • 10.1. Pain Management
    • 10.1.1. Cancer Pain
    • 10.1.2. Chronic Noncancer Pain
  • 10.2. Spasticity Management
    • 10.2.1. Cerebral Palsy
    • 10.2.2. Multiple Sclerosis
    • 10.2.3. Spinal Cord Injury

11. Intrathecal Pumps Market, by End User

  • 11.1. Ambulatory Surgical Centers
  • 11.2. Hospitals
  • 11.3. Specialty Clinics

12. Intrathecal Pumps Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Intrathecal Pumps Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Intrathecal Pumps Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Intrathecal Pumps Market

16. China Intrathecal Pumps Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott Laboratories
  • 17.6. Arrow International, Inc.
  • 17.7. Arthrex, Inc.
  • 17.8. B. Braun Melsungen AG
  • 17.9. Baxter International Inc.
  • 17.10. Becton Dickinson and Company
  • 17.11. Boston Scientific Corporation
  • 17.12. Durect Corporation
  • 17.13. Flowonix Medical, Inc.
  • 17.14. Fresenius Kabi AG
  • 17.15. Johnson & Johnson Services Inc.
  • 17.16. Medallion Therapeutics, Inc.
  • 17.17. Medtronic plc
  • 17.18. Smiths Medical
  • 17.19. Teleflex Inc.
  • 17.20. Terumo Corporation
  • 17.21. Tricumed Medizintechnik GmbH
  • 17.22. Zimmer Biomet Holdings, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL INTRATHECAL PUMPS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL INTRATHECAL PUMPS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL INTRATHECAL PUMPS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY PUMP TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY DRUG TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY THERAPY AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES INTRATHECAL PUMPS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA INTRATHECAL PUMPS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL INTRATHECAL PUMPS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY PUMP TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY EXTERNAL PUMPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY EXTERNAL PUMPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY EXTERNAL PUMPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY IMPLANTABLE PUMPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY IMPLANTABLE PUMPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY IMPLANTABLE PUMPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY BACLOFEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY BACLOFEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY BACLOFEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY LOCAL ANESTHETICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY LOCAL ANESTHETICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY LOCAL ANESTHETICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY OPIOIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY OPIOIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY OPIOIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY CANCER PAIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY CANCER PAIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY CANCER PAIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY CHRONIC NONCANCER PAIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY CHRONIC NONCANCER PAIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY CHRONIC NONCANCER PAIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY CEREBRAL PALSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY CEREBRAL PALSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY CEREBRAL PALSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY SPINAL CORD INJURY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY SPINAL CORD INJURY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY SPINAL CORD INJURY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. AMERICAS INTRATHECAL PUMPS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 55. AMERICAS INTRATHECAL PUMPS MARKET SIZE, BY PUMP TYPE, 2018-2032 (USD MILLION)
  • TABLE 56. AMERICAS INTRATHECAL PUMPS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 57. AMERICAS INTRATHECAL PUMPS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 58. AMERICAS INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 59. AMERICAS INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 60. AMERICAS INTRATHECAL PUMPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 61. NORTH AMERICA INTRATHECAL PUMPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. NORTH AMERICA INTRATHECAL PUMPS MARKET SIZE, BY PUMP TYPE, 2018-2032 (USD MILLION)
  • TABLE 63. NORTH AMERICA INTRATHECAL PUMPS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 64. NORTH AMERICA INTRATHECAL PUMPS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 65. NORTH AMERICA INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 66. NORTH AMERICA INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 67. NORTH AMERICA INTRATHECAL PUMPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 68. LATIN AMERICA INTRATHECAL PUMPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. LATIN AMERICA INTRATHECAL PUMPS MARKET SIZE, BY PUMP TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. LATIN AMERICA INTRATHECAL PUMPS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 71. LATIN AMERICA INTRATHECAL PUMPS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 72. LATIN AMERICA INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 73. LATIN AMERICA INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 74. LATIN AMERICA INTRATHECAL PUMPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE, MIDDLE EAST & AFRICA INTRATHECAL PUMPS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE, MIDDLE EAST & AFRICA INTRATHECAL PUMPS MARKET SIZE, BY PUMP TYPE, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA INTRATHECAL PUMPS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA INTRATHECAL PUMPS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA INTRATHECAL PUMPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE INTRATHECAL PUMPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE INTRATHECAL PUMPS MARKET SIZE, BY PUMP TYPE, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE INTRATHECAL PUMPS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE INTRATHECAL PUMPS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE INTRATHECAL PUMPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. MIDDLE EAST INTRATHECAL PUMPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. MIDDLE EAST INTRATHECAL PUMPS MARKET SIZE, BY PUMP TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. MIDDLE EAST INTRATHECAL PUMPS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 92. MIDDLE EAST INTRATHECAL PUMPS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 93. MIDDLE EAST INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 94. MIDDLE EAST INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 95. MIDDLE EAST INTRATHECAL PUMPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 96. AFRICA INTRATHECAL PUMPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. AFRICA INTRATHECAL PUMPS MARKET SIZE, BY PUMP TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. AFRICA INTRATHECAL PUMPS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 99. AFRICA INTRATHECAL PUMPS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 100. AFRICA INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 101. AFRICA INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 102. AFRICA INTRATHECAL PUMPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC INTRATHECAL PUMPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC INTRATHECAL PUMPS MARKET SIZE, BY PUMP TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC INTRATHECAL PUMPS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC INTRATHECAL PUMPS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC INTRATHECAL PUMPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. ASEAN INTRATHECAL PUMPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. ASEAN INTRATHECAL PUMPS MARKET SIZE, BY PUMP TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. ASEAN INTRATHECAL PUMPS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. ASEAN INTRATHECAL PUMPS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 115. ASEAN INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 116. ASEAN INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 117. ASEAN INTRATHECAL PUMPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 118. GCC INTRATHECAL PUMPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GCC INTRATHECAL PUMPS MARKET SIZE, BY PUMP TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. GCC INTRATHECAL PUMPS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. GCC INTRATHECAL PUMPS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 122. GCC INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 123. GCC INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 124. GCC INTRATHECAL PUMPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPEAN UNION INTRATHECAL PUMPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPEAN UNION INTRATHECAL PUMPS MARKET SIZE, BY PUMP TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPEAN UNION INTRATHECAL PUMPS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPEAN UNION INTRATHECAL PUMPS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPEAN UNION INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPEAN UNION INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPEAN UNION INTRATHECAL PUMPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. BRICS INTRATHECAL PUMPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. BRICS INTRATHECAL PUMPS MARKET SIZE, BY PUMP TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. BRICS INTRATHECAL PUMPS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. BRICS INTRATHECAL PUMPS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 136. BRICS INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 137. BRICS INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 138. BRICS INTRATHECAL PUMPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 139. G7 INTRATHECAL PUMPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. G7 INTRATHECAL PUMPS MARKET SIZE, BY PUMP TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. G7 INTRATHECAL PUMPS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. G7 INTRATHECAL PUMPS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 143. G7 INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 144. G7 INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 145. G7 INTRATHECAL PUMPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. NATO INTRATHECAL PUMPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. NATO INTRATHECAL PUMPS MARKET SIZE, BY PUMP TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. NATO INTRATHECAL PUMPS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. NATO INTRATHECAL PUMPS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 150. NATO INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 151. NATO INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 152. NATO INTRATHECAL PUMPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. UNITED STATES INTRATHECAL PUMPS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 155. UNITED STATES INTRATHECAL PUMPS MARKET SIZE, BY PUMP TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. UNITED STATES INTRATHECAL PUMPS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. UNITED STATES INTRATHECAL PUMPS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 158. UNITED STATES INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 159. UNITED STATES INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 160. UNITED STATES INTRATHECAL PUMPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. CHINA INTRATHECAL PUMPS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 162. CHINA INTRATHECAL PUMPS MARKET SIZE, BY PUMP TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. CHINA INTRATHECAL PUMPS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. CHINA INTRATHECAL PUMPS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 165. CHINA INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 166. CHINA INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 167. CHINA INTRATHECAL PUMPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)